Heparanase-2 Expression in Normal Ovarian Epithelium and in Benign and Malignant Ovarian Tumors

被引:13
作者
de Moura, Joel Pereira, Jr. [1 ]
Nicolau, Sergio Mancini [1 ]
Stavale, Joao Norberto [2 ]
da Silva Pinhal, Maria Aparecida [3 ]
de Matos, Leandro Luongo [4 ]
Baracat, Edmund Chada [1 ]
de Lima, Geraldo Rodrigues [1 ]
机构
[1] Univ Fed Sao Paulo, Dept Gynecol, Escola Paulista Med, BR-04037005 Sao Paulo, Brazil
[2] Univ Fed Sao Paulo, Dept Pathol, Escola Paulista Med, BR-04037005 Sao Paulo, Brazil
[3] Univ Fed Sao Paulo, Dept Biochem, Escola Paulista Med, BR-04037005 Sao Paulo, Brazil
[4] ABC Fdn, Dept Biochem, Mol Biol Lab, Fac Med, Sao Paulo, Brazil
关键词
Ovarian neoplasia; Heparanase; 2; Extracellular matrix; Heparan sulfate; Proteoglycans; MAMMALIAN HEPARANASE; BASEMENT-MEMBRANES; SULFATE; INVASION; METASTASIS; PERLECAN; CLONING; GROWTH;
D O I
10.1111/IGC.0b013e3181a834a2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Studies have highlighted the changes that take place in the environment between the cell and the extracellular matrix during the process of neoplastic expansion. Several papers have associated the expression of heparanase 1 with various malignant tumors. Heparanase 2 is probably related to loss of cell adhesion. Objective: The aim of this study was to evaluate the expression of heparanase 2 in epithelial neoplasia of the ovaries and in samples of normal ovarian tissue. Methods: Seventy-five ovary specimens were analyzed and divided into 3 groups: 23 malignant and 35 benign epithelial ovarian neoplasia and 17 without ovarian disease. We used 2 methodological techniques for evaluating the immunoexpression of heparanase 2. The first followed the qualitative criterion of positive or negative in relation to enzymatic expression, and the second involved computerized quantification of this expression, performed on the same slides. Results: In the quantitative analysis, we found positivity indices for heparanase 2 expression of 72.2% and 87.3% in the samples of benign and malignant neoplasias, respectively. In these,the intensity of expression and the expression index were 147.2 and 121.2. respectively, for the benign neoplasia and 134.1 and 118.0 for the malignant neoplasia. Qualitatively, its expression was strong or moderate in 44.2% of the benign and 78.2% of the malignant tumors; its expression in all of the nonneoplastic samples was negative, with the exception of one that was weakly positive. Conclusions: Heparanase 2 is involved in neoplastic proliferation, but it was not exclusively associated with the malignant process. Furthermore, there was no difference in its expression between benign and malignant ovarian epithelial neoplasia.
引用
收藏
页码:1494 / 1500
页数:7
相关论文
共 50 条
[41]   Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer [J].
Zheng, Hong ;
Hu, Wei ;
Deavers, Michael T. ;
Shen, De-Yu ;
Fu, Siqing ;
Li, Yan-Fang ;
Kavanagh, John J. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2009, 201 (04) :367.e1-367.e6
[42]   Heparanase expression in malignant salivary gland tumors inversely correlates with long-term survival [J].
Ben-Izhak, Ofer ;
Kaplan-Cohen, Victoria ;
Ilan, Neta ;
Gan, Shlomit ;
Vlodavsky, Israel ;
Nagler, Rafael .
NEOPLASIA, 2006, 8 (10) :879-884
[43]   The Expression of Markers Related to Ovarian Germline Stem Cells in the Mouse Ovarian Surface Epithelium and the Correlation with Notch Signaling Pathway [J].
Pan, Zezheng ;
Sun, Mengli ;
Li, Jia ;
Zhou, Fangyue ;
Liang, Xia ;
Huang, Jian ;
Zheng, Tuochen ;
Zheng, Liping ;
Zheng, Yuehui .
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2015, 37 (06) :2311-2322
[44]   High expression of EZH2 as a marker for the differential diagnosis of malignant and benign myogenic tumors [J].
Zhang, Ning ;
Zeng, Zhi ;
Li, Shaobo ;
Wang, Fei ;
Huang, Peng .
SCIENTIFIC REPORTS, 2018, 8
[45]   Mendelian randomization analysis to explore the relationship between cathepsins and malignant ovarian tumors [J].
Ying, Jiaqi ;
Chen, Xia ;
Lv, Tian ;
Jie, Fang ;
Tian, Huanyong .
MEDICINE, 2024, 103 (46) :e40219
[46]   KNDC1 Is a Predictive Marker of Malignant Transformation in Borderline Ovarian Tumors [J].
Yu, Shuqian ;
Shen, Jiayu ;
Fei, Jing ;
Zhu, Xiaoqing ;
Yin, Meichen ;
Zhou, Jianwei .
ONCOTARGETS AND THERAPY, 2020, 13 :709-718
[47]   Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors [J].
Erickson-Miller, Connie L. ;
Pillarisetti, Kodandaram ;
Kirchner, Jennifer ;
Figueroa, David J. ;
Ottesen, Lone ;
Martin, Anne-Marie ;
Liu, Yuan ;
Kamel, Yasser Mostafa ;
Messam, Conrad .
BMC CANCER, 2012, 12
[48]   CXCL12 expression by healthy and malignant ovarian epithelial cells [J].
Machelon, Veronique ;
Gaudin, Francoise ;
Camilleri-Broet, Sophie ;
Nasreddine, Salam ;
Bouchet-Delbos, Laurence ;
Pujade-Lauraine, Eric ;
Alexandre, Jerome ;
Gladieff, Laurence ;
Arenzana-Seisdedos, Fernando ;
Emilie, Dominique ;
Prevot, Sophie ;
Broet, Philippe ;
Balabanian, Karl .
BMC CANCER, 2011, 11
[49]   Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors:: correlation with Ki-67 and p53 immunoreactivity [J].
Bar, JK ;
Grelewski, P ;
Popiela, A ;
Noga, L ;
Rabczyñski, J .
GYNECOLOGIC ONCOLOGY, 2004, 95 (01) :23-31
[50]   Expression of Adiponectin and Its Receptors Is Altered in Epithelial Ovarian Tumors and Ascites-Derived Ovarian Cancer Cell Lines [J].
Tiwari, Anupama ;
Ocon-Grove, Olga M. ;
Hadley, Jill A. ;
Giles, James R. ;
Johnson, Patricia A. ;
Ramachandran, Ramesh .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (03) :399-406